IGHV3-23: The Potential Drug Target and Biomarker (G28442)

Target Name: IGHV3-23

NCBI ID: G28442

IGHV3-23

IGHV3-23: The Potential Drug Target and Biomarker

Immunoglobulin heavy chain (IgH) genes are a part of the immune system that produce antibodies to fight against various pathogens. One of the most common genetic variations in the IGH family is IGHV3-23. This genetic variation has been identified as a potential drug target and biomarker for several studies. In this article, we will discuss the IGHV3-23 genetic variation, its potential as a drug target, and its role as a biomarker for various diseases.

IGHV3-23 Genetic Variation

IGHV3-23 is a genetic variation that is found in approximately 10% of the population. It is a single nucleotide polymorphism (SNP) that results in a change in the amino acid sequence of the constant region of the IGH molecule. Specifically, IGHV3-23 results in the substitution of the amino acid Asp for Asn at position 23.

IGHV3-23 has been shown to have several unique properties that could make it an attractive drug target. One of the most significant properties is its ability to interact with various drug molecules. IGHV3-23 has been shown to have a high affinity for small molecules, such as inhibitors, making it a potential drug target for diseases that are characterized by the overuse of these molecules.

Another property that makes IGHV3-23 an attractive drug target is its role in the development of cancer. Several studies have shown that IGHV3-23 is associated with an increased risk of cancer development in individuals with certain genetic variations. For example, one study found that individuals with the IGHV3-23 variation had an increased risk of gastric cancer compared to those without the variation.

IGHV3-23 as a Biomarker

IGHV3-23 has also been shown to be a potential biomarker for several diseases. For example, one study found that individuals with IGHV3-23 had an increased risk of developing cardiovascular disease compared to those without the variation. This suggests that IGHV3-23 may be a useful biomarker for diseases that are characterized by an increased risk of cardiovascular disease.

Another study found that individuals with IGHV3-23 had an increased risk of developing neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that IGHV3-23 may be a useful biomarker for neurodegenerative diseases.

Conclusion

In conclusion, IGHV3-23 is a genetic variation that has been shown to have several unique properties that make it an attractive drug target. Its ability to interact with various drug molecules and its role in the development of cancer and neurodegenerative diseases make IGHV3-23 a promising candidate for drug development. Further research is needed to fully understand the potential of IGHV3-23 as a drug target and biomarker.

Protein Name: Immunoglobulin Heavy Variable 3-23

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets